26 jan: Villa Joy - dansk konceptbolig med verdensinspiration og potentia..
02 feb: Stort behov for mini-MBA i bestyrelsesuddannelse
28-01-2010 08:02:00

Preliminary Annual Accounts / Fourth Quarter Report 2009

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

Rieber & Søn's operating profit (EBIT) in the fourth quarter totalled NOK 185m

(122m), while the figure for the year was NOK 424m (356m). EPS in the fourth

quarter stood at  NOK 1.52  (0.82) and NOK 3.32 (2.46) for the year.

Sales in the fourth quarter came to NOK 1 256m (1 377m), while the figure for

the year was NOK 4 967m (4 997m). Structural effects had a negative effect on

sales, reducing the performance by 1.6% in the fourth quarter, and by 0.6% for

the year. Currency conversion effects reduced sales in the fourth quarter by

4.7% and by 0.4% for the year. Organic growth stood at -2.4% in the fourth

quarter, while the increase for the year was 0.4%.

The gross margin in the fourth quarter rose to 59.2% (57.1%) and to 56.7%

(56,0%) for the year. The Group had good cost control in the fourth quarter and

payroll and operating costs were down 8% at NOK 569m, while the figure for the

year was 1% lower at NOK 2 218m. The EBITDA margin for the fourth quarter was

13,9% (12.1%) and 12.1% (11.2%) for the year. The corresponding figures for

 EBIT margin were 14.7% (8.9%) and 8.5% (7.1%), respectively.

The operating profit in the fourth quarter was positively affected by one-off

effects which contributed NOK 61m. This was the net effect of income of NOK 77m

from the sale of the  Sopps brand and the marine ingredients line in Arna, and

costs of NOK 16m related to the write-down of the production plant for Anja Cake

in Poland and transaction costs for the acquisition of Gellwe which was not

approved by the Polish competition authorities.  The operating profit for the

year was positively affected by one-off effects totalling NOK 32m. The Group's

core activities exclusive one-off items provided EPS of NOK 3.09 for the year,

which was 30% up on 2008.

The return on capital employed was 22.7% (14.1%) in the fourth quarters and

12.8% (10.9%) for the year.

In line with the Group's dividend policy, the Board will ask the AGM to approve

a dividend of NOK 2.00 per share. Together, this represents a 60% increase in

the dividend compared with the previous year and a dividend ratio of 60%.

"Our Future"

"Our Future" is aimed at achieving lasting improvements in results of NOK 400m

in 2012. The extra consumption of resources of a one-time nature in order to

realise these improvements is estimated to cost NOK 125m. The programme is

progressing as planned.

In the fourth quarter, the net effect of improvements in purchasing, production

and marketing under the "Our Future" platform totalled NOK 35m and comprised

positive effects of NOK 44m in the fourth quarter and implementation costs of

NOK 9m. The accumulated total of the positive, lasting effects in the first 12

months was NOK 96m, while implementation costs in the same period came to NOK

47m.

The aim to improve Group profitability was achieved in line with the plans for

2009. Through good cost control and the implementation of efficiency programmes

which provide lasting improvements, a sound basis has been laid for further

growth in profitability.

Bergen, 27 January 2010

Board of Directors of Rieber & Søn ASA

[HUG#1377906]

4Q Quarter Report 2009 : http://hugin.info/121/R/1377906/338577.pdf

4Q Presentation 2009: http://hugin.info/121/R/1377906/338578.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
30
10 dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
08 dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
07 dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
12 dec
GEN
Minder lige om denne fra d. 21.11.2017:http://medwatch.dk/Medicinal___Biotek/article10047753.ece   "..
14
09 dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14

Aktier/tendens: Ørsted kan ryge til vejrs i ellers haltende åbning

14-12-2017 08:19:22
En forventet stigning til energiselskabet Ørsted kan næppe ændre ved det samlede billede for det danske aktiemarked, som torsdag morgen ser ud til at starte let haltende og måske med en lille pil nedad. Det sker oven på en onsdag, hvor det ledende C20 cap-indeks gik ned på grund af tekniske problemer og hen over eftermiddagen ikke blev opdateret. Senere blev det dog opgjort til at være lukket i 11..

Harboes H1: Dårligt sommervejr ramte både omsætningen og indtjeningen

13-12-2017 15:48:19
Dårligt sommervejr i Nordeuropa ramte både omsætningen og indtjeningen hos Harboes Bryggeri, der har haft et markant dårligere første halvår af det skæve regnskabsår 2017/18 sammenlignet med for et år siden.Nettoomsætningen fra maj til udgangen af oktober faldt til 696,4 mio. kr. mod 744,6 mio. kr. i samme periode året forinden, fremgår det af halvårsregnskabet for 2017/18 onsdag eftermiddag.På de..

Novo-rival spår effekt af ugentligt GLP-1 på linje med Ozempics

13-12-2017 13:30:09
Novo Nordisks store franske rival Sanofi forudser, at dens ugentlige GLP-1-analog, Efpeglenatid, har en effekt på langtidsblodsukkeret, der er på linje Novos nye ugentlige diabetes 2-middel Ozempic, som tilhører samme lægemiddelklasse.Det fremgår af en præsentation under et analytikerarrangement onsdag, hvor Sanofi fremlægger sin forsknings- og udviklingsstrategi for de kommende år.Sanofi indledte..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får sin største ordre nogensinde i Indien - NY
2
Vestas rykker nærmere kæmpekontrakter i New Mexico og Texas
3
Onsdagens aktier: Genmab endnu engang til bunds i negativt marked
4
Aktier: C20 og kompagni lagt ned i timevis af teknisk uheld - NY4
5
Aktier/tendens: Ørsted kan ryge til vejrs i ellers haltende åbning

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
14. december 2017 11:02:41
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB5 - 2017-12-14 11:02:41 - 2017-12-14 11:02:41 - 1 - Website: OKAY